Market Place
Sourcing Support
Sparsentan Receives Orphan Drug Designation for IgA Nephropathy
03 Dec 2024 //
PR NEWSWIRE
Travere Therapeutics to Present Abstracts at ASN Kidney Week 2024
14 Oct 2024 //
GLOBENEWSWIRE
Travere`s Benralizumab Receives Approval in the U.S.
17 Sep 2024 //
FDA
Ligand Partner Travere Gets Full FDA Approval For FILSPARI In IgA
06 Sep 2024 //
BUSINESSWIRE
Despite trial scare, Travere`s IgAN drug wins full FDA approval
06 Sep 2024 //
FIERCE PHARMA
Travere Therapeutics Reports Second Quarter 2024 Financial Results
01 Aug 2024 //
GLOBENEWSWIRE
Travere To Present At Kidney Meetings In Spring 2024
09 May 2024 //
GLOBENEWSWIRE
Travere Therapeutics Reports First Quarter 2024 Financial Results
06 May 2024 //
GLOBENEWSWIRE
FILSPARI Approved in EU for IgA Nephropathy
24 Apr 2024 //
PR NEWSWIRE
Renalys Submits an IND App for a Ph III Trial of sparsentan for IgA Nephropathy
07 Apr 2024 //
PR NEWSWIRE
Travere to Present Abstracts on FILSPARI in IgA Nephropathy at World Congress
03 Apr 2024 //
GLOBENEWSWIRE
Travere Submits sNDA to the FDA Seeking Full Approval of FILSPARI
11 Mar 2024 //
GLOBENEWSWIRE
Travere drug for rare kidney condition recommended for EU approval
24 Feb 2024 //
REUTERS
Travere`s Filspari misses the mark in rare kidney disease trial
22 Sep 2023 //
FIERCE PHARMA
Travere Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI
21 Sep 2023 //
GLOBENEWSWIRE
Travere fails to beat off-label blood pressure drug in phase 3
03 May 2023 //
FIERCE BIOTECH
Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Ph 3 DUPLEX
02 May 2023 //
PR NEWSWIRE
Travere Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI
01 Apr 2023 //
GLOBENEWSWIRE
Travere turns BMS castoff into rare kidney disease approval
18 Feb 2023 //
FIERCE PHARMA
Travere Announces FDA Acceptance and Priority Review of NDA for Sparsentan
16 May 2022 //
BIOSPACE
Travere Tx Submits NDA for Sparsentan for IgA Nephropathy
21 Mar 2022 //
GLOBENEWSWIRE
Vifor doles out $55M upfront to license Travere`s asset
16 Sep 2021 //
FIERCEBIOTECH
Travere Therapeutics highlights FDA Type A meeting outcome for sparsentan
07 Sep 2021 //
SEEKINGALPHA
Sparsentan Granted Orphan Drug Status for IgA Nephropathy
12 Jan 2021 //
EMPR
Retrophin sheds Shkreli connection with new name: Travere
17 Nov 2020 //
FIERCE BIOTECH
Retrophin no more: Shkreli`s legacy disappears as former company Travere
16 Nov 2020 //
ENDPTS
Retrophin Completes Acquisition of Orphan TechnologiesAddition of OT-58
12 Nov 2020 //
BIOSPACE
Retrophin Buys Orphan Technologies for $517 Million to Gain Enzyme Therapy
23 Oct 2020 //
BIOSPACE
Retrophin Announces Agreement to Acquire Orphan Technologies
23 Oct 2020 //
PRESS RELEASE
Retrophin beefs up the rare disease drug pipeline with a $517M buyout deal
23 Oct 2020 //
PRESS RELEASE
Retrophin Announces Agreement to Acquire Orphan Technologies
22 Oct 2020 //
BIOSPACE
Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined
09 Oct 2020 //
GLOBENEWSWIRE
